Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567740 | 0.92 | MAP2K1 (0.46) | MAP2K1 | |
| SCHEMBL2565186 | 0.84 | MAP2K1 (0.46) | MAP2K1BRAFEIF2AK3 | |
| SCHEMBL2559561 | 0.83 | MAP2K1 (0.42) | MAP2K1BRAFEIF2AK3 | |
| SCHEMBL2565053 | 0.81 | MAP2K1 (0.44) | MAP2K1BRAFEIF2AK3 | |
| SCHEMBL2562264 | 0.76 | MAP2K1 (0.40) | MAP2K1BRAFEIF2AK3 | |
| SCHEMBL2565520 | 0.75 | MAP2K1 (0.52) | MAP2K1BRAFEIF2AK3 | |
| SCHEMBL2567742 | 0.75 | MAP2K1 (0.57) | MAP2K1 | |
| SCHEMBL4552188 | 0.75 | MAP2K1 (0.48) | MAP2K1 | |
| SCHEMBL2565971 | 0.75 | MAP2K1 (0.45) | MAP2K1BRAFEIF2AK3 | |
| SCHEMBL2569311 | 0.74 | MAP2K1 (0.45) | MAP2K1BRAFEIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069354-B1 | Aza-benzofuranyl compounds and methods of use | GENENTECH INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | MAP2K1 10/4885BRAF 42/4885EIF2AK3 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.